Phase II Study of KRP-209- A Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Efficacy and Safety of KRP-209 in Patients with Subjective Tinnitus
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2016
At a glance
- Drugs Neramexane (Primary)
- Indications Tinnitus
- Focus Therapeutic Use
- Sponsors Kyorin Pharmaceutical
- 02 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record
- 05 Nov 2015 Status changed from not yet recruiting to recruiting.